Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZTLWT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
huDS6v1.21-DM4
|
|||||
| Synonyms |
huDS6v1.21 DM4
Click to Show/Hide
|
|||||
| Organization |
Sanofi SA
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 5 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Cervical cancer [ICD11:2C77]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Structure |
|
|||||
| Antibody Name |
huDS6v1.21
|
Antibody Info | ||||
| Antigen Name |
Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Ravtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.